

Table 4A Associations between epicardial adipose tissue volume and presence of coronary artery plaque (plaque scores >0 vs. 0) among HIV seronegative

	Coronary artery calcium (<i>N</i> = 352) (Prevalence = 53%)		Noncalcified plaque (<i>N</i> = 284) (Prevalence = 54%)		Calcified plaque (<i>N</i> = 284) (Prevalence = 40%)		Mixed plaque (<i>N</i> = 284) (Prevalence = 32%)		Any plaque (<i>N</i> = 284) (Prevalence = 76%)	
	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>
Model 1	1.05 (1–1.1)	0.065	1.06 (1.01–1.12)	0.025	1.01 (0.96–1.07)	0.67	1.02 (0.96–1.08)	0.51	1.07 (1–1.15)	0.059
Model 2	1.00 (0.95–1.05)	0.95	1.06 (1–1.13)	0.043	0.98 (0.92–1.04)	0.47	0.98 (0.92–1.05)	0.58	1.04 (0.96–1.12)	0.36
Model 3	0.97 (0.91–1.03)	0.34	1.09 (1.02–1.16)	0.015	0.96 (0.89–1.03)	0.22	0.99 (0.92–1.06)	0.72	1.04 (0.95–1.13)	0.43
Model 4	1.00 (0.94–1.07)	0.96	1.10 (1.02–1.18)	0.008	0.97 (0.9–1.04)	0.37	0.99 (0.92–1.06)	0.71	1.06 (0.97–1.17)	0.21

Table 4B Associations between epicardial adipose tissue volume and presence of coronary artery plaque (plaque scores >0 vs. 0) among HIV seropositive

	Coronary artery calcium (<i>N</i> = 579) (Prevalence = 53%)		Noncalcified plaque (<i>N</i> = 422) (Prevalence = 64%)		Calcified plaque (<i>N</i> = 422) (Prevalence = 34%)		Mixed plaque (<i>N</i> = 422) (Prevalence = 35%)		Any plaque (<i>N</i> = 422) (Prevalence = 78%)	
	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>
Model 1	1.04 (1.01–1.08)	0.02	1.06 (1.02–1.11)	0.005	1.05 (1.01–1.09)	0.015	1.02 (0.98–1.06)	0.27	1.10 (1.04–1.16)	0.001
Model 2	1.01 (0.98–1.05)	0.45	1.06 (1.01–1.10)	0.02	1.03 (0.99–1.07)	0.19	1.01 (0.97–1.05)	0.60	1.08 (1.02–1.15)	0.009
Model 3	1.03 (0.99–1.07)	0.20	1.05 (1.00–1.10)	0.054	1.03 (0.98–1.07)	0.29	1.02 (0.98–1.07)	0.31	1.07 (1.01–1.15)	0.03
Model 4	1.02 (0.98–1.07)	0.27	1.04 (0.99–1.10)	0.15	1.02 (0.97–1.08)	0.36	1.01 (0.97–1.07)	0.57	1.06 (0.98–1.14)	0.12

Table 5A Associations between epicardial adipose tissue volume and extent of plaque among those with any plaque present (plaque score >0) among HIV seronegative

	Coronary artery calcium (N = 185)		Noncalcified Plaque Score (N = 152)		Calcified Plaque Score (N = 114)		Mixed Plaque Score (N = 92)		Total Plaque Score (N = 215)	
	Effect estimate (SE)	P	Effect estimate (SE)	P	Effect estimate (SE)	P	Effect estimate (SE)	P	Effect estimate (SE)	P
Model 1	0.030 (0.024)	0.21	0.030 (0.010)	0.003	0.009 (0.016)	0.59	0.004 (0.018)	0.83	0.030 (0.012)	0.01
Model 2	0.017 (0.028)	0.53	0.016 (0.010)	0.14	−0.005 (0.018)	0.77	0.000 (0.02)	0.98	0.012 (0.012)	0.34
Model 3	0.014 (0.030)	0.64	0.013 (0.012)	0.29	0.000 (0.019)	0.99	−0.024 (0.022)	0.28	0.006 (0.014)	0.66
Model 4	0.009 (0.033)	0.78	0.008 (0.012)	0.50	−0.002 (0.020)	0.90	−0.011 (0.023)	0.61	0.006 (0.014)	0.67

Table 5B Associations between epicardial adipose tissue volume and extent of plaque among those with any plaque present (plaque score >0) among HIV seropositive

	Coronary artery calcium (N = 308)		Noncalcified Plaque Score (N = 271)		Calcified Plaque Score (N = 145)		Mixed Plaque Score (N = 147)		Total Plaque Score (N = 330)	
	Effect estimate (SE)	P	Effect estimate (SE)	P	Effect estimate (SE)	P	Effect estimate (SE)	P	Effect estimate (SE)	P
Model 1	0.056 (0.016)	<0.001	0.002 (0.008)	0.75	0.009 (0.011)	0.400	0.005 (0.010)	0.64	0.015 (0.008)	0.055
Model 2	0.049 (0.016)	0.002	−0.003 (0.008)	0.66	0.005 (0.012)	0.64	−0.002 (0.011)	0.88	0.005 (0.008)	0.54
Model 3	0.054 (0.017)	0.002	0.002 (0.009)	0.85	0.003 (0.012)	0.81	0.004 (0.012)	0.70	0.012 (0.009)	0.20
Model 4	0.067 (0.019)	<0.001	0.002 (0.010)	0.87	0.010 (0.014)	0.48	−0.007 (0.013)	0.58	0.010 (0.01)	0.32